Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study

Abstract Background Nivolumab and cabozantinib are currently approved agents in metastatic renal cell carcinoma (mRCC) but there are no data available for patients progressing to both treatments. The aim of this study was to compare active therapeutic options and best supportive care (BSC) after pro...

Full description

Bibliographic Details
Main Authors: Giandomenico Roviello, Elisabetta Gambale, Roberta Giorgione, Daniele Santini, Marco Stellato, Giuseppe Fornarini, Sara Elena Rebuzzi, Umberto Basso, Davide Bimbatti, Laura Doni, Gabriella Nesi, Melissa Bersanelli, Sebastiano Buti, Ugo De Giorgi, Luca Galli, Andrea Sbrana, Raffaele Conca, Claudia Carella, Emanuele Naglieri, Sandro Pignata, Giuseppe Procopio, Lorenzo Antonuzzo
Format: Article
Language:English
Published: Wiley 2022-08-01
Series:Cancer Medicine
Subjects:
fourth‐line therapy
immune checkpoint inhibitors
metastatic renal cell carcinoma
targeted therapy
tyrosine kinase inhibitors
vascular endothelial growth factor receptor
Online Access:https://doi.org/10.1002/cam4.4681

Internet

https://doi.org/10.1002/cam4.4681

Similar Items